BCIQ Profiles

Company Profile Report
0329 Product Dev QTs
BioCentury & Getty Images

Product Development

March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure

Mar 29, 2021 | 11:38 PM GMT

Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized patients with COVID-19, meeting the Phase III trial’s

Read the full 612 word article

How to gain access

Continue reading with a
two-week free trial.